New single cell and spatial innovations extend
10x Genomics' technology and performance
leadership across all three platforms
PLEASANTON, Calif., Feb. 23,
2025 /PRNewswire/ -- At the Advances in Genome
Biology and Technology (AGBT) General Meeting, 10x Genomics, Inc.
(Nasdaq: TXG), a leader in single cell and spatial biology,
announced a series of new product innovations to solidify its
position as the best partner for high-performance single cell
research at scale. In addition, the company unveiled a robust new
product roadmap for its Visium and Xenium portfolios, extending its
performance and technology leadership in the rapidly growing field
of spatial biology.
"After a record year of innovation, we continue to push the
boundaries of what's possible in single cell and spatial biology,
taking on the hardest challenges so researchers can make the
biggest impact," said Ben Hindson,
Co-Founder and Chief Scientific Officer of 10x Genomics. "Our 2025
roadmap will once again raise the bar for the field and enable
researchers to tackle bigger questions, analyze more samples and
extract deeper insights from their data."
10x Genomics will host a workshop at AGBT today, Sunday, February 23, at 1
p.m. ET to share the latest data and development directions
across its three platforms. This workshop will be
live-streamed beginning at 1:30 p.m.
ET for researchers not attending AGBT.
Advancing Large-Scale Single Cell Research
Building on a record year of Chromium product releases in 2024,
10x Genomics announced plans to enable high-performance, mega-scale
single cell analysis with improved efficiency and ease of use.
Highlights of 10x's forthcoming innovations in single cell analysis
include:
- Plate-based workflows for Chromium GEM-X Flex: The
company announced plans for plate-based GEM-X Flex workflows
designed to massively expand the number of samples per run. At
launch, this plate-based workflow will enable more than 700 samples
in a single run. Researchers will be able to use plate-based GEM-X
Flex to recover approximately 1 million cells from a single lane
and 8 million cells per chip. Unlike alternative offerings, the
plate-based approach on GEM-X Flex will be a highly parallel
workflow that does not require using an entire plate at once,
giving researchers full control and flexibility over how they
design and scale their studies. Researchers will also be able to
partition millions of cells in minutes using Chromium X and iX
instruments as part of this plate-based workflow.
Optimized for a wide range of large-scale studies, including
perturbation screens and large sample cohorts, the GEM-X Flex
plate-based workflow is expected to deliver top-tier sensitivity,
high quality data and best-in-class sequencing efficiency to ensure
superior results at scale.
- 10x Cloud Analysis for Large Studies will give
researchers even more scalable ways to manage large datasets,
including a new batch analysis feature for running hundreds or
thousands of analyses in parallel. 10x Genomics Cloud Analysis
already provides researchers with access to robust computational
resources in a simple web interface. Cloud Analysis for Large
Studies will help researchers looking to automate data processing
programmatically while taking advantage of 10x Cloud's
high-performance infrastructure. These capabilities will be
available to support both the Chromium and Visium platforms.
Once launched, these offerings will join a broad portfolio of
recent Chromium innovations intended to democratize access to
single cell analysis by delivering high performance and low cost at
any scale. These include:
- GEM-X Flex Gene Expression, which enables mega-scale single
cell research for as low as one cent
per cell.
- GEM-X Universal Multiplex, featuring on-chip multiplexing so
researchers can easily batch and run four independent samples, up
to 5,000 cells per sample, for approximately $600 per sample, at any scale.
- Chromium Xo, a high-powered instrument at a low-cost entry
point so more researchers can access the performance and workflow
advantages of Chromium single cell analysis.
Expanding Technology Leadership in Spatial Biology
10x Genomics continues to lead the spatial biology revolution
with a broad portfolio of easy-to-use technologies that enable
superior performance and provide deeper, high resolution insights
into tissue organization and function.
Visium Platform
In 2024, 10x Genomics launched its groundbreaking Visium HD
product, increasing the resolution of the Visium platform by over
three orders of magnitude. Now compatible with FFPE, Fresh Frozen
and Fixed Frozen tissues, Visium HD delivers high sensitivity and
sequencing efficiency with the proven CytAssist-enabled workflow.
10x Genomics revealed today several planned additions to the Visium
HD platform, including:
- Visium HD 3' for high resolution, species-agnostic spatial
profiling: 10x Genomics unveiled its plans to bring its
flagship Visium v1 3' assay, launched in 2019, into high resolution
with improvements in both performance and workflow. The forthcoming
Visium HD 3' assay is a reverse transcription-based approach to
whole transcriptome spatial profiling at single cell scale. Visium
HD 3' is designed to enable de novo discovery across a broad
range of applications, such as analysis of isoforms and long
non-coding RNAs. Visium HD 3' will deliver both high resolution and
high sensitivity in a diverse set of species and a wide range of
fresh frozen tissues. Powered by Visium CytAssist, Visium HD 3'
will give researchers a streamlined workflow featuring same-section
H&E staining on standard glass slides and no tissue
optimization required.
- Visium HD Cell Segmentation for morphology-guided spatial
transcriptomics: Visium HD Cell Segmentation leverages H&E
images from the same tissue section and high spatial fidelity
enabled by CytAssist to resolve spatial transcriptomics data at
single-cell scale. This approach enables researchers to assign
transcripts to individual cells with precision, improving
clustering and characterization of cellular heterogeneity within
tissues. By integrating gene expression with morphology-driven
segmentation, researchers can uncover new cell populations and
spatial interactions that were previously masked.
- Visium HD XL: The company also highlighted Visium HD XL,
which will feature an expanded capture area to enable whole
transcriptome spatial gene expression analysis of larger tissue
sections at single-cell-scale resolution.
Xenium Platform
- Xenium RNA+Protein Multiomics: 10x Genomics shared plans
to enable simultaneous detection of RNA and proteins on the same
slide and tissue section to unlock multiomic insights into cellular
function at subcellular resolution. In a single Xenium run,
researchers will be able to seamlessly integrate RNA and proteins
and preserve the high data quality they have come to expect from
the platform. The validated plug-and-play protein immunology panel
for human FFPE tissues will include seven modular subpanels
covering up to 28 protein targets to eliminate the burden of assay
development and optimization. It is designed to complement a broad
Xenium menu of curated, semi-custom and fully custom RNA v1 panels
to maximize data quality and workflow efficiency.
10x Genomics at AGBT
Throughout AGBT, 10x Genomics will host a series of scientific
presentations and events to showcase how its latest technologies
are driving biological discovery:
- Pre-Conference Workshop: Revving up insights in single
cell and spatial exploration (February 23,
2025). Register for the livestream here.
- Featured Posters:
- Poster 457: GEM-X Universal Multiplex: A cost-effective,
sample- and species- agnostic multiplexing approach for single-cell
RNA sequencing
- Poster 439: In Situ detection of HPV expression in human
cervical cancer with Xenium Prime 5K
- Poster 432: Exploring tumor microenvironment heterogeneity
through multiomic In Situ profiling of RNA and proteins
About 10x Genomics
10x Genomics is a life science technology company building
products to accelerate the mastery of biology and advance human
health. Our integrated solutions include instruments, consumables
and software for single cell and spatial biology, which help
academic and translational researchers and biopharmaceutical
companies understand biological systems at a resolution and scale
that matches the complexity of biology. Our products are behind
breakthroughs in oncology, immunology, neuroscience and more,
fueling powerful discoveries that are transforming the world's
understanding of health and disease. To learn more, visit
10xgenomics.com or connect with us on LinkedIn, X (Twitter),
Facebook, Bluesky or YouTube.
Forward Looking Statements
This press release contains
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995 as contained in Section
27A of the Securities Act of 1933, as amended, and Section 21E of
the Securities Exchange Act of 1934, as amended, which fall under
the "safe harbor" provisions of those sections. All statements,
other than statements of historical facts, may be forward-looking
statements. Forward-looking statements generally can be identified
by the use of forward-looking terminology such as "may," "might,"
"will," "should," "expect," "plan," "anticipate," "could,"
"intend," "target," "project," "contemplate," "believe,"
"estimate," "predict," "potential" or "continue" or variations of
them or similar terminology, but the absence of these words does
not mean that a statement is not forward-looking. These
forward-looking statements include statements regarding 10x
Genomics, Inc.'s ("10x Genomics") product launches, performance,
scale, configuration, costs, capabilities, adoption and pipeline.
These statements are based on management's current expectations,
forecasts, beliefs, assumptions and information currently available
to management, and actual outcomes and results could differ
materially from these statements due to a number of factors. Other
risks and uncertainties that could affect 10x Genomics' financial
and operating results and cause actual results to differ materially
from those indicated by the forward-looking statements made in this
press release include those discussed under the captions "Risk
Factors" and "Management's Discussion and Analysis of Financial
Condition and Results of Operations" and elsewhere in the documents
10x Genomics files with the Securities and Exchange Commission (the
"SEC") from time to time. Although 10x Genomics believes that the
expectations reflected in the forward-looking statements are
reasonable, it cannot provide any assurance that these expectations
will prove to be correct nor can it guarantee that the future
results, levels of activity, performance and events and
circumstances reflected in the forward-looking statements will be
achieved or occur. The forward-looking statements in this press
release are based on information available to 10x Genomics as of
the date hereof, and 10x Genomics disclaims any obligation to
update any forward-looking statements provided to reflect any
change in its expectations or any change in events, conditions or
circumstances on which any such statement is based, except as
required by law. These forward-looking statements should not be
relied upon as representing 10x Genomics' views as of any date
subsequent to the date of this press release.
Disclosure Information
10x Genomics uses filings with
the Securities and Exchange Commission, our website
(www.10xgenomics.com), press releases, public conference calls,
public webcasts and our social media accounts as means of
disclosing material non-public information and for complying with
our disclosure obligations under Regulation FD.
Contacts
Investors: investors@10xgenomics.com
Media: media@10xgenomics.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/10x-genomics-unveils-innovation-roadmap-at-agbt-general-meeting-advancing-leadership-in-large-scale-single-cell-and-spatial-analysis-302382827.html
SOURCE 10x Genomics, Inc.
